Switch theme
Sign up to access all valuation multiples
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
2002
368
LTM Revenue $206M
LTM EBITDA n/a
-$108M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vanda Pharmaceuticals has a last 12-month revenue of $206M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vanda Pharmaceuticals achieved revenue of $199M and an EBITDA of -$32.5M.
Vanda Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vanda Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $193M | $199M | XXX | XXX | XXX |
| Gross Profit | $230M | $178M | XXX | XXX | XXX |
| Gross Margin | 119% | 89% | XXX | XXX | XXX |
| EBITDA | -$10.9M | -$32.5M | XXX | XXX | XXX |
| EBITDA Margin | -6% | -16% | XXX | XXX | XXX |
| Net Profit | $6.3M | $2.5M | XXX | XXX | XXX |
| Net Margin | 3% | 1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vanda Pharmaceuticals's stock price is $4.
Vanda Pharmaceuticals has current market cap of $254M, and EV of -$108M.
See Vanda Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$108M | $254M | XXX | XXX | XXX | XXX | $-0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vanda Pharmaceuticals has market cap of $254M and EV of -$108M.
Vanda Pharmaceuticals's trades at -0.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vanda Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vanda Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$108M | XXX | XXX | XXX |
| EV/Revenue | -0.5x | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | XXX | XXX |
| P/E | -13.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVanda Pharmaceuticals's NTM/LTM revenue growth is 22%
Vanda Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Vanda Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vanda Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vanda Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 197% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 6% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 115% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vanda Pharmaceuticals acquired XXX companies to date.
Last acquisition by Vanda Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Vanda Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vanda Pharmaceuticals founded? | Vanda Pharmaceuticals was founded in 2002. |
| Where is Vanda Pharmaceuticals headquartered? | Vanda Pharmaceuticals is headquartered in United States of America. |
| How many employees does Vanda Pharmaceuticals have? | As of today, Vanda Pharmaceuticals has 368 employees. |
| Who is the CEO of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's CEO is Dr. Mihael Hristos Polymeropoulos,M.D.. |
| Is Vanda Pharmaceuticals publicy listed? | Yes, Vanda Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Vanda Pharmaceuticals? | Vanda Pharmaceuticals trades under VNDA ticker. |
| When did Vanda Pharmaceuticals go public? | Vanda Pharmaceuticals went public in 2006. |
| Who are competitors of Vanda Pharmaceuticals? | Similar companies to Vanda Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's current market cap is $254M |
| What is the current revenue of Vanda Pharmaceuticals? | Vanda Pharmaceuticals's last 12-month revenue is $206M. |
| What is the current EV/Revenue multiple of Vanda Pharmaceuticals? | Current revenue multiple of Vanda Pharmaceuticals is -0.5x. |
| What is the current revenue growth of Vanda Pharmaceuticals? | Vanda Pharmaceuticals revenue growth between 2023 and 2024 was 3%. |
| Is Vanda Pharmaceuticals profitable? | Yes, Vanda Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
